News

New immuno-pet tracer superior to FDG PET in predicting PD-L1 expression in head and neck cancer
PCP2, can effectively measure PD-L1 expression in patients with head and neck cancers, outperforming the conventional tracer ...
Yahoo Finance14d
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative ...
VIENNA, Va., June 18, 2025--FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine.
Medscape Reference9d
PD-L1 Did Not Predict Immunotherapy Benefit in Cervical Cancer
A post hoc analysis of the BEATcc trial showed that atezolizumab plus chemotherapy and bevacizumab provided clinical benefit ...
Yahoo Finance1mon
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation - Yahoo Finance
About APVO711. Novel Mechanism: APVO711 is a bispecific antibody targeting PD-L1 × CD40-combining checkpoint inhibition with immune activation in a single molecule. Designed for Potency: Unlike ...
Business Wire3mon
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications - Business Wire
PD-L1 is a critical biomarker for potential response to anti-PD-1 therapies, which are revolutionizing the treatment of cancer. Pathology labs play an important role in informing treatment decisions.
Cure Today3mon
Solnerstotug Demonstrates Early Efficacy in PD-L1 Resistant Tumors
Additionally, six PD-L1–resistant patients with stable disease remain on treatment past 12 or more weeks, with tumor reductions ranging from 0% to 17%, suggesting durable disease control in a subset ...
Medscape9mon
Ivonescimab Tops Pembro in Advanced PD-L1-Positive NSCLC - Medscape
The investigational PD-1/VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced PD-L1-positive NSCLC.
Morningstar1mon
Clinical Trials Demonstrate Monitoring PD-L1 Upregulation Using LifeTracDx Blood Test Could Support New Treatment Path for Metastatic Triple Negative Breast Cancer - Morningstar
Clinical Trials Demonstrate Monitoring PD-L1 Upregulation Using LifeTracDx Blood Test Could Support New Treatment Path for Metastatic Triple Negative Breast Cancer. PR Newswire.
The American Journal of Managed Care4mon
First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1
Tislelizumab, combined with chemotherapy, is now FDA-approved for first-line treatment of unresectable or metastatic ESCC with PD-L1 expression. The phase 3 RATIONALE-306 study demonstrated ...
FiercePharma2mon
Summit stock falls as Akeso shares bispecific overall survival data
In announcing (Chinese) ivonescimab’s Chinese approval in first-line PD-L1-positive non-small cell lung cancer on Friday, Akeso noted that the bispecific drug slashed the risk of death by 22.3% ...
FierceBiotech11mon
Incyte drops two PD-L1 drugs as part of 2nd pipeline clear-out - Fierce Biotech
Incyte drops pair of PD-L1 drugs as part of 2nd pipeline clear-out this year. By James Waldron Jul 30, 2024 8:14am. Incyte PD-L1 checkpoint inhibitors solid tumor. For ...
Healio9mon
FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy - Healio
The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection.The agent (Tecentriq Hybreza, Genentech) is the first subcutaneous anti-PD-L1 cancer immunotherapy approved in the ...